Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides customer with cutting-edge CellRapeutics™ Chimeric Antigen Receptor (CAR) against a series of Germ cell tumor specific antigens, which is based on a great amount of researches and many years of experience. As a reputable service provider, we are dedicated to highly tailored service in order to meet your unique requirements.
Fig.1 CAR T cell engineering.1
Germ cell tumor (GCT) is a rare kind of cancer which derives from germ cells, which can be benign or malignant (cancer). The most common categories are testicular germ cell tumors (seminoma and non-seminoma) and ovarian germ cell tumors, however they can also spread to other parts of the body which leads to various symptoms. The etiology of germ cell tumor is still unclear. The treatment for germ cell tumor usually includes surgery, chemotherapy, radiation, bone marrow transplantation or a combination of these approaches. However, these traditional treatments are not highly effective and can cause the risk of potential complications. In decades, GCT therapy is focused on adaptive immunotherapy, such as chimeric antigen receptor (CAR)-engineered T cells or NK cells, which have been showing remarkable promise for treating cancer. Creative Biolabs, as a leading technology provider, offers a variety of CARs targeting GCT-specific antigens.
With a great team of excellent scientists, we can provide customers with the highest quality bespoke CAR construction service according to your special needs.
Products ordering information
Please note: Besides the CARs targeting GCT-specific antigens listed below, we also provide highly customized service tailored to your research, diagnostic and therapeutic application purposes. We look forward to hearing from you.
| Associated malignancy | Target antigen | Receptor type | Product |
| Ovarian cancer | mesothelin | scFv-CD28-41BB-CD3ζ | CAR-T-3-M321-2BZ |
| FRα | scFv-CD28-41BB-CD3ζ | CAR-T-3-M313-2BZ | |
| Bpep | scFv-CD28-41BB-CD3ζ | CAR-T-3-M402-2BZ | |
| CLDN6 | scFv-CD28-41BB-CD3ζ | CAR-LC192 | |
| B7-H4 | scFv--CD28-CD3ζ | CAR-LC240 | |
| LHR | scFv-CD28-41BB-CD3ζ | CAR-LC249 | |
| MUC16 | scFv-CD28-41BB-CD3ζ | CAR-MZ194 | |
| Alpha(v) beta(6) integrin (αvβ6) | Bpep-CD4TM-CD3ζ | CAR-MZ229 | |
| NKG2D ligands | NKG2D receptor-CD28-CD3ζ | CAR-MZ233 |
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
